Expression-enhanced polypeptides

US8518403B2 · kind B2 · utility

Assignee

• AMGEN RESEARCH (MUNICH) GMBH · DE

Inventors

• Patrick Hoffmann · Munich, DE
• Silke Mittelstrass · Birkenfeld, DE
• Jens Hennecke · Birkenfeld, DE
• Tobias Raum · Munich, DE

Key dates

• Filing date: Jul 15, 2005
• Grant date: Aug 27, 2013
• Expiry date: Mar 3, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

A composite polypeptide, said composite polypeptide comprising a desired polypeptide and an expression enhancing domain (“EED”), said EED comprising first and second cysteine amino acid residues Cys1 and Cys2, respectively, Cys1 being located closer to the N-terminus of the composite polypeptide molecule than Cys2, wherein Cys1 and Cys2 are separated by a polypeptide linker, said linker—being free of cysteine and proline;—defining a length sufficient to allow Cys1 and Cys2 to engage in an intramolecular disulfide bond with one another; and—having a flexible polypeptide conformation essentially free of secondary polypeptide structure in aqueous solution, wherein at least one of Cys1 and Cys2 is derivatized with a derivatization moiety.